Biotech financing activity is rebounding early in 2026, with total biopharma financings reaching $22.82 billion in Q1 2026, up about 74% from $13.12 billion in Q1 2025 but down 31% from the $33.16 billion seen in Q4 2025, according to deal-finance tracking summarized in the report. The figure positions 2026 above subdued levels from 2022–2025. The data point to a meaningful restart of capital formation as IPO and follow-on windows reopen, even as deal volumes remain below earlier peaks in 2021 and 2024. For biotech operators, the report suggests a market that is restarting—though not fully normalized—across public and private financing channels. This financing backdrop is relevant for companies moving into later-stage trials, where timelines and capital planning depend heavily on how quickly investors return for large rounds.